

FILE 'HCAPLUS' ENTERED AT 13:28:33 ON 09 MAY 2008

L1	255	S	DEXTRAN(3A) (PHOSPHATE OR PHOSPHORYLAT?)
L2	1068809	S	IMMUN?
L3	832905	S	COLITIS OR VIRUS OR VIRAL OR BACTERIAL OR INFECTION
L4	114106	S	ALLERG? OR ASTHMA OR RHINITIS OR DERMATITIS
L5	27	S	L1 AND L2
L6	6	S	L1 AND L2 AND L3
L7	1	S	L1 AND L2 AND L4

=> file hcaplus		
COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	0.63	0.63

FILE 'HCAPLUS' ENTERED AT 13:28:33 ON 09 MAY 2008
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
 COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 9 May 2008 VOL 148 ISS 20
 FILE LAST UPDATED: 8 May 2008 (20080508/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s dextran(3a)(phosphate or phosphorylat?)

```

          38826 DEXTRAN
          595423 PHOSPHATE
          207579 PHOSPHORYLAT?
L1          255 DEXTRAN(3A)(PHOSPHATE OR PHOSPHORYLAT?)

```

=> s immun?

```

L2          1068809 IMMUN?

```

=> s colitis or virus or viral or bacterial or infection

```

          13573 COLITIS
          385815 VIRUS
          186307 VIRAL
          290960 BACTERIAL
          309141 INFECTION
L3          832905 COLITIS OR VIRUS OR VIRAL OR BACTERIAL OR INFECTION

```

=> s allerg? or asthma or rhinitis or dermatitis

```

          77997 ALLERG?
          39491 ASTHMA
          7903 RHINITIS
          20665 DERMATITIS
L4          114106 ALLERG? OR ASTHMA OR RHINITIS OR DERMATITIS

```

=> s l1 and l2

```

L5          27 L1 AND L2

```

=> s l1 and l2 and l3

L6 6 L1 AND L2 AND L3

=> s l1 and l2 and l4

L7 1 L1 AND L2 AND L4

=> file stnguide0

'STNGUIDE0' IS NOT A VALID FILE NAME

SESSION CONTINUES IN FILE 'HCAPLUS'

Enter "HELP FILE NAMES" at an arrow prompt (=>) for a list of files that are available. If you have requested multiple files, you can specify a corrected file name or you can enter "IGNORE" to continue accessing the remaining file names entered.

=> d l6 1-6 ti abs bib

L6 ANSWER 1 OF 6 HCAPLUS COPYRIGHT 2008 ACS on STN

TI Phosphorylated dextran as immunopotentiator

AB It is clarified that an immunopotential activity can be imparted to dextran, which shows no immunol. activity, by chemical phosphorylating it. The phosphorylated dextran is a B cell mitogen, activates dendritic cells and induces IL-10 and IFN- γ . Thus, it is expected as being effective in preventing infectious diseases and colitis and preventing allergic diseases by maintaining the Th1/2 balance. Phosphorylated dextran was prepared from dextran and polyphosphoric acid, and its blastogenic effect on mouse spleen cells was examined

AN 2004:80514 HCAPLUS <<LOGINID::20080509>>

DN 140:151931

TI Phosphorylated dextran as immunopotentiator

IN Saito, Tadao; Kitazawa, Haruki

PA Meiji Dairies Corporation, Japan

SO PCT Int. Appl., 51 pp.

CODEN: PIXXD2

DT Patent

LA Japanese

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004009099	A1	20040129	WO 2003-JP9324	20030723
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
	JP 2004107316	A	20040408	JP 2003-50739	20030227
	AU 2003252244	A1	20040209	AU 2003-252244	20030723
	EP 1543833	A1	20050622	EP 2003-765361	20030723
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK			
	US 20060154896	A1	20060713	US 2005-522047	20051020
PRAI	JP 2002-213305	A	20020723		
	JP 2003-50739	A	20030227		

RE.CNT 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 2 OF 6 HCAPLUS COPYRIGHT 2008 ACS on STN

TI Dextran-binding human plasma antibody recognizes bacterial and yeast antigens and is inhibited by glucose concentrations reached in diabetic sera

AB Dextran-binding antibody was isolated in high yield from plasma of all 40 blood donors screened in a South Indian population. The antibody was purified by a single step affinity chromatog. on Sephadex G100 using 1-O-Me α -D-glucoside as eluant. Anal. of protein peaks obtained in size exclusion high pressure liquid chromatog. (HPLC) revealed dominance of IgG and suggested the presence of polymeric IgA in this antibody. Me and para-nitrophenyl α -D-glucosides, in contrast to their β -anomers, were very efficient inhibitors of binding of this antibody to dextran. Galactose and glucose were equally good inhibitors. Among disaccharide inhibitors sucrose was more efficient than maltose or melibiose. Hb artificially glycosylated to contain covalently-linked glucose or α -anomeric galactose was sugar-specifically recognized by this antibody. Galactose moieties in glycoproteins or polysaccharides were, however, not recognized. The dextran-binding antibody bound sugar-specifically to glycoconjugates from yeast (*Saccharomyces cerevisiae*) and to lipopolysaccharides from *Klebsiella* and group A *Streptococci*, but not to lipopolysaccharides from *E. coli*. Inhibition studies suggested glucose moiety with unsubstituted C2 and C4 and α -anomeric C1 as ideal for recognition by the dextran-binding antibody. Concentration of glucose required for 50% inhibition of binding of the

purified antibody to polystyrene-coated dextran in phosphate buffered saline was above the glucose concns. in normal sera, but well below those reached in diabetic sera. Binding of the antibody from dialysed plasma to immobilized dextran was lowered only marginally in presence of glucose at 4.5 mM (which nears normal serum glucose concns.), but substantially in presence of the sugar at 20 mM and above which are reached in diabetic sera. If verified in vivo, inhibition of this antibody by high serum glucose may possibly be among reasons for the increased susceptibility of diabetics to infection.

AN 2003:284826 HCAPLUS <<LOGINID::20080509>>

DN 139:51440

TI Dextran-binding human plasma antibody recognizes bacterial and yeast antigens and is inhibited by glucose concentrations reached in diabetic sera

AU Chacko, B. K.; Appukuttan, P. S.

CS Division of Biochemistry, Sree Chitra Tirunal Institute for Medical Sciences and Technology, Thiruvananthapuram, 695011, India

SO Molecular Immunology (2003), 39(15), 933-939

CODEN: MOIMD5; ISSN: 0161-5890

PB Elsevier Science Ltd.

DT Journal

LA English

RE.CNT 23 THERE ARE 23 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 3 OF 6 HCAPLUS COPYRIGHT 2008 ACS on STN

TI Phosphorylated sugar alcohols from basidiomycetes and dextran as antiviral drugs and health foods

AB Phosphorylated sugar alcs. (including β -glucan)from basidiomycetes and dextran prepared by pretreatment with $ZnCl_2$ and urea melting or enzyme method are claimed as antiviral drugs (e.g. against HIV1) and health foods.

AN 2003:166958 HCAPLUS <<LOGINID::20080509>>
 DN 138:163508
 TI Phosphorylated sugar alcohols from basidiomycetes and dextran as antiviral
 drugs and health foods
 IN Akabane, Toru; Kitani, Yoshiyasu; Baba, Masanori; Tadano, Toshio
 PA Uma K. K., Japan
 SO Jpn. Kokai Tokkyo Koho, 4 pp.
 CODEN: JKXXAF
 DT Patent
 LA Japanese
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	----	-----	-----	-----
PI	JP 2003063968	A	20030305	JP 2001-295057	20010823
PRAI	JP 2001-295057		20010823		

L6 ANSWER 4 OF 6 HCAPLUS COPYRIGHT 2008 ACS on STN
 TI Intestinal infection with Giardia spp. reduces epithelial
 barrier function in a myosin light chain kinase-dependent fashion
 AB Giardiasis causes malabsorptive diarrhea, and symptoms can be present in
 the absence of any significant morphol. injury to the intestinal mucosa.
 The effects of giardiasis on epithelial permeability in vivo remain
 unknown, and the role of T cells and myosin light chain kinase (MLCK) in
 altered intestinal barrier function is unclear. This study was conducted
 to determine whether Giardia spp. alters intestinal permeability in vivo, to
 assess whether these abnormalities are dependent on T cells, and to assess
 the role of MLCK in altered epithelial barrier function.
 Immunocompetent and isogenic athymic mice were inoculated with
 axenic Giardia muris trophozoites or sterile vehicle (control), then
 assessed for trophozoite colonization and gastrointestinal permeability.
 Mechanistic studies using nontransformed human duodenal epithelial
 monolayers (SCBN) determined the effects of Giardia on myosin light chain (MLC)
 phosphorylation, transepithelial fluorescein isothiocyanate-
 dextran fluxes, cytoskeletal F-actin, tight junctional zonula
 occludens-1 (ZO-1), and MLCK. Giardia infection caused a
 significant increase in small intestinal, but not gastric or colonic,
 permeability that correlated with trophozoite colonization in both
 immunocompetent and athymic mice. In vitro, Giardia increased
 permeability and phosphorylation of MLC and reorganized F-actin and ZO-1.
 These alterations were abolished with an MLCK inhibitor. Conclusions:
 Disruption of small intestinal barrier function is T cell independent,
 disappears on parasite clearance, and correlates with reorganization of
 cytoskeletal F-actin and tight junctional ZO-1 in an MLCK-dependent
 fashion.

AN 2002:839408 HCAPLUS <<LOGINID::20080509>>
 DN 138:120766
 TI Intestinal infection with Giardia spp. reduces epithelial
 barrier function in a myosin light chain kinase-dependent fashion
 AU Scott, Kevin G.-E.; Meddings, Jonathon B.; Kirk, David R.; Lees-Miller,
 Susan P.; Buret, Andre G.
 CS Department of Biological Sciences, University of Calgary, AB, Can.
 SO Gastroenterology (2002), 123(4), 1179-1190
 CODEN: GASTAB; ISSN: 0016-5085
 PB W. B. Saunders Co.
 DT Journal
 LA English
 RE.CNT 60 THERE ARE 60 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 5 OF 6 HCAPLUS COPYRIGHT 2008 ACS on STN
 TI Expression of antibodies in mammalian cells

AB The authors discuss different factors to be considered when making the transition from bacterial recombinant V region manipulation to mammalian complete antibody expression. These factors include the antibody constant region to be used, the promoter to be used, transient or stable expression, mammalian selectable markers, and testing antibody production. Protocols for transfection using DEAE-dextran and calcium phosphate are given.

AN 2001:477140 HCAPLUS <<LOGINID::20080509>>

DN 136:133294

TI Expression of antibodies in mammalian cells

AU Bradbury, Andrew

CS Biosciences Division, Los Alamos National Laboratory, Los Alamos, NM, 87545, USA

SO Antibody Engineering (2001), 357-366. Editor(s): Kontermann, Roland; Duebel, Stefan. Publisher: Springer-Verlag, Berlin, Germany.

CODEN: 69BLB8

DT Conference

LA English

RE.CNT 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD

ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 6 OF 6 HCAPLUS COPYRIGHT 2008 ACS on STN

TI A microtransfection method using the luciferase-encoding reporter gene for the assay of human immunodeficiency virus LTR promoter activity

AB A microtransfection method, using either the DEAE-dextran or the Ca phosphate procedure has been developed. A plasmid expressing the luciferase-encoding gene under the control of the human immunodeficiency virus (HIV) LTR promoter was constructed. Transfections were performed in 96-well plates, allowing statistical evaluation of the results. This microtransfection method requires the use of 100- to 1000-fold less plasmid and cells than in a conventional chloramphenicol acetyl transferase (CAT) assay. A luciferase index which takes into account cell viability after transfection has been defined using a semi-automated absorbance assay. A 20-h incubation period post-transfection is sufficient for optimal results. Basal long terminal repeat activity and autologous Tat transactivation were studied in various lymphoid, monocytic and adherent human cell lines. Infection of microtransfected cells by HIV activated luc expression. This assay can thus also be used for rapid detection and quantitation of HIV. Antiviral activities of drugs can be assessed in a two-day test.

AN 1990:472465 HCAPLUS <<LOGINID::20080509>>

DN 113:72465

OREF 113:12137a,12140a

TI A microtransfection method using the luciferase-encoding reporter gene for the assay of human immunodeficiency virus LTR promoter activity

AU Schwartz, Olivier; Virelizier, Jean Louis; Montagnier, Luc; Hazan, Uriel

CS Unite Oncol. Virale, Inst. Pasteur, Paris, 75724, Fr.

SO Gene (1990), 88(2), 197-205

CODEN: GENED6; ISSN: 0378-1119

DT Journal

LA English

=> d 17 ti abs bib

L7 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2008 ACS on STN

TI Phosphorylated dextran as immunopotentiator

AB It is clarified that an immunopotential activity can be

imparted to dextran, which shows no immunol. activity, by chemical phosphorylating it. The phosphorylated dextran is a B cell mitogen, activates dendritic cells and induces IL-10 and IFN- γ . Thus, it is expected as being effective in preventing infectious diseases and colitis and preventing allergic diseases by maintaining the Th1/2 balance. Phosphorylated dextran was prepared from dextran and polyphosphoric acid, and its blastogenic effect on mouse spleen cells was examined

AN 2004:80514 HCAPLUS <<LOGINID::20080509>>
 DN 140:151931
 TI Phosphorylated dextran as immunopotentiator
 IN Saito, Tadao; Kitazawa, Haruki
 PA Meiji Dairies Corporation, Japan
 SO PCT Int. Appl., 51 pp.
 CODEN: PIXXD2
 DT Patent
 LA Japanese
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	----	-----	-----	-----
PI	WO 2004009099	A1	20040129	WO 2003-JP9324	20030723
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	JP 2004107316	A	20040408	JP 2003-50739	20030227
	AU 2003252244	A1	20040209	AU 2003-252244	20030723
	EP 1543833	A1	20050622	EP 2003-765361	20030723
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	US 20060154896	A1	20060713	US 2005-522047	20051020
PRAI	JP 2002-213305	A	20020723		
	JP 2003-50739	A	20030227		
	WO 2003-JP9324	W	20030723		

RE.CNT 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT